摘要
目的:探讨德谷胰岛素利拉鲁肽治疗血糖控制不佳的肥胖2型糖尿病的效果。方法:选择2021年8月至2023年5月该院收治的血糖控制不佳的肥胖2型糖尿病患者84例,采用随机数字表法分为观察组42例、对照组42例。对照组患者采用甘精胰岛素注射液联合沙格列汀片治疗,观察组患者采用德谷胰岛素利拉鲁肽注射液联合沙格列汀片治疗,两组患者均治疗12周。比较两组患者的临床疗效和不良反应发生情况,血糖达标率、体重指数、糖化血红蛋白、空腹血清C肽(FCP)、血清2 h C肽(2 hPCP)、空腹血糖、空腹胰岛素水平及胰岛素抵抗指数。结果:治疗后,观察组患者的总有效率为90.48%(38/42),高于对照组的71.43%(30/42),差异有统计学意义(P<0.05)。观察组患者治疗6、12周后,血糖达标率高于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组患者的体重指数、空腹血糖水平和胰岛素抵抗指数低于对照组,FCP、2 hPCP和空腹胰岛素水平高于对照组,差异均有统计学意义(P<0.05);两组患者糖化血红蛋白水平的差异无统计学意义(P>0.05)。两组患者低血压发生率、不良反应发生率的差异均无统计学意义(P>0.05)。结论:德谷胰岛素利拉鲁肽能够有效改善血糖控制不佳的肥胖2型糖尿病患者的血糖水平,提高临床疗效,降低患者体重指数及胰岛素抵抗指数,不良反应少。
OBJECTIVE:To probe into the effects of Tegu insulin liraglutide in the treatment of obese type 2 diabetes mellitus with poor glycemic control.METHODS:A total of 84 obese type 2 diabetes patients with poor glycemic control admitted into the hospital from Aug.2021 to May 2023 were extracted to be divided into the observation group(42 cases)and control group(42 cases)by the random number table method.The control group was treated with insulin glargine injection combined with Saxagliptin tablets,while the observation group received Tegu insulin liraglutide injection combined with Saxagliptin tablets,both groups were treated for 12 weeks.The clinical efficacy and the occurrence of adverse drug reactions,blood glucose compliance rate,body mass index,glycosylated hemoglobin,fasting C-peptide(FCP),2 h C-peptide(2 hPCP)level,fasting blood glucose,fasting insulin and insulin resistance index were compared between two groups.RESULTS:After treatment,the total effective rate of observation group was 90.48%(38/42),higher than 71.43%(30/42)of control group,with statistically significant difference(P<0.05).The blood glucose compliance rate of observation group at 6 and 12 weeks after treatment was higher than that of control group,with statistically significant difference(P<0.05).After treatment,the levels of body mass index,fasting blood glucose and insulin resistance index in observation group were lower than those in control group,while the levels of FCP,2 hPCP and fasting insulin were higher than those in control group,with statistically significant differences(P<0.05).There was no significant difference in glycosylated hemoglobin HBA1c level between two groups(P>0.05).There were no significant differences in the incidence of hypotension and adverse drug reactions between two groups(P>0.05).CONCLUSIONS:Tegu insulin liraglutide can effectively improve the blood glucose level in obese type 2 diabetes patients with poor glycemic control,improve clinical efficacy,reduce body mass index and insulin resistance index,and reduce adv
作者
刘文清
张文谨
毕菲菲
LIU Wenqing;ZHANG Wenjin;BI Feifei(Dept.of Pharmacy,Tangshan Hospital of Traditional Chinese Medicine,Hebei Tangshan 063000,China;Dept.of Endocrinology,Tangshan Hospital of Traditional Chinese Medicine,Hebei Tangshan 063000,China)
出处
《中国医院用药评价与分析》
2024年第10期1208-1211,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
河北省自然科学基金青年基金项目(No.H2020209288)。
关键词
德谷胰岛素利拉鲁肽
血糖控制不佳
2型糖尿病
临床疗效
血糖水平
胰岛素抵抗指数
Tegu insulin liraglutide
Poor glycemic control
Type 2 diabetes mellitus
Clinical efficacy
Blood glucose level
Insulin resistance index
